Assessing essentiality of transketolase in Mycobacterium tuberculosis using an inducible protein degradation system

FEMS Microbiology Letters

Volumn 358, Issue 1, 2014, Pages 30-35

  Kolly, Gaëlle S ^a   Sala, Claudia ^a   Vocat, Anthony ^a   Cole, Stewart T ^a  

^a EPFL   (Switzerland)

Author keywords

Mycobacterium tuberculosis; Conditional mutant; Transketolase Tkt; Tuberculosis

Indexed keywords

TRANSKETOLASE;

ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; CONTROLLED STUDY; DOWN REGULATION; GENETIC PROCEDURES; IN VITRO STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RNA SILENCING AND PROTEIN DEGRADATION SYSTEM; TET PIP OFF SYSTEM; TKT GENE; CELL LINE; ENZYMOLOGY; ESSENTIAL GENE; GENE SILENCING; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; MICROBIAL VIABILITY; MICROBIOLOGY; MONOCYTE; PHYSIOLOGY; VIRULENCE;

CELL LINE; GENE SILENCING; GENES, ESSENTIAL; HUMANS; MICROBIAL VIABILITY; MONOCYTES; MYCOBACTERIUM TUBERCULOSIS; PROTEOLYSIS; TRANSKETOLASE; VIRULENCE;

EID: 84908292785     PISSN: 03781097     EISSN: 15746968     Source Type: Journal    
DOI: 10.1111/1574-6968.12536     Document Type: Article

References (16)

1. Beste DJ, Espasa M, Bonde B, Kierzek AM, Stewart GR & McFadden J (2009) The genetic requirements for fast and slow growth in mycobacteria. PLoS ONE 4: e5349.
2. Boldrin F, Casonato S, Dainese E, Sala C, Dhar N, Palu G, Riccardi G, Cole ST & Manganelli R (2010) Development of a repressible mycobacterial promoter system based on two transcriptional repressors. Nucleic Acids Res 38: e134.
3. Chen JM, Boy-Rottger S, Dhar N, Sweeney N, Buxton RS, Pojer F, Rosenkrands I & Cole ST (2012) EspD is critical for the virulence-mediating ESX-1 secretion system in Mycobacterium tuberculosis. J Bacteriol 194: 884-893.
4. Cole ST, Brosch R, Parkhill J et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544.
5. Forti F, Crosta A & Ghisotti D (2009) Pristinamycin-inducible gene regulation in mycobacteria. J Biotechnol 140: 270-277.
6. Fullam E, Pojer F, Bergfors T, Jones TA & Cole ST (2011) Structure and function of the transketolase from Mycobacterium tuberculosis and comparison with the human enzyme. Open Biol 2: 110026.
7. Gandotra S, Schnappinger D, Monteleone M, Hillen W & Ehrt S (2007) In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat Med 13: 1515-1520.
8. Kim JH, Wei JR, Wallach JB, Robbins RS, Rubin EJ & Schnappinger D (2011) Protein inactivation in mycobacteria by controlled proteolysis and its application to deplete the beta subunit of RNA polymerase. Nucleic Acids Res 39: 2210-2220.
9. Kim JH, O'Brien KM, Sharma R et al. (2013) A genetic strategy to identify targets for the development of drugs that prevent bacterial persistence. P Natl Acad Sci USA 110: 19095-19100.
10. Klotzsche M, Ehrt S & Schnappinger D (2009) Improved tetracycline repressors for gene silencing in mycobacteria. Nucleic Acids Res 37: 1778-1788.
11. Kolly GS, Boldrin F, Sala C, Dhar N, Hartkoorn RC, Ventura M, Serafini A, McKinney JD, Manganelli R & Cole ST (2014) Assessing the essentiality of the decaprenyl-phospho-d-arabinofuranose pathway in Mycobacterium tuberculosis using conditional mutants. Mol Microbiol 92: 194-211.
12. Stallings CL, Stephanou NC, Chu L, Hochschild A, Nickels BE & Glickman MS (2009) CarD is an essential regulator of rRNA transcription required for Mycobacterium tuberculosis persistence. Cell 138: 146-159.
13. Wei JR, Krishnamoorthy V, Murphy K, Kim JH, Schnappinger D, Alber T, Sassetti CM, Rhee KY & Rubin EJ (2011) Depletion of antibiotic targets has widely varying effects on growth. P Natl Acad Sci USA 108: 4176-4181.
14. WHO (2012) Global Tuberculosis Report 2012. WHO, Geneva.
15. Zhao G & Winkler ME (1994) An Escherichia coli K-12 tktA tktB mutant deficient in transketolase activity requires pyridoxine (vitamin B6) as well as the aromatic amino acids and vitamins for growth. J Bacteriol 176: 6134-6138.
16. Zumla A, Nahid P & Cole ST (2013) Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov 12: 388-404.